{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:18:51Z","timestamp":1792030731012,"version":"4.4.0"},"reference-count":15,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bras Pneumol."],"abstract":"<jats:p>Idiopathic pulmonary arterial hypertension (PAH) patients with a positive response to acute vasodilator challenge and a clinical response to calcium channel blockers (CCBs) for at least one year are traditionally designated true responders. Nevertheless, little is known about a sustained response to CCBs over longer periods of time. We evaluated the loss of response to CCBs after long-term treatment in a cohort of idiopathic PAH patients previously classified as being true responders. Our data suggest that idiopathic PAH patients can lose clinical response to CCBs even after one year of clinical stability, reinforcing the need for constant multidimensional reevaluation to assess the need for targeted PAH therapies and to classify these patients correctly.<\/jats:p>","DOI":"10.36416\/1806-3756\/e20220337","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T16:47:22Z","timestamp":1678985242000},"page":"e20220337","source":"Crossref","is-referenced-by-count":2,"title":["Loss of response to calcium channel blockers after long-term follow-up treatment in patients with idiopathic pulmonary arterial hypertension"],"prefix":"10.36416","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8756-0400","authenticated-orcid":false,"given":"Bruna","family":"Piloto1","sequence":"first","affiliation":[{"name":"1. Divis\u00e3o de Pneumologia, Instituto do Cora\u00e7\u00e3o, Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4912-021X","authenticated-orcid":false,"given":"Caio","family":"Julio Cesar dos Santos Fernandes1","sequence":"additional","affiliation":[{"name":"1. Divis\u00e3o de Pneumologia, Instituto do Cora\u00e7\u00e3o, Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0425-5548","authenticated-orcid":false,"given":"Carlos","family":"Jardim1","sequence":"additional","affiliation":[{"name":"1. Divis\u00e3o de Pneumologia, Instituto do Cora\u00e7\u00e3o, Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9373-3937","authenticated-orcid":false,"given":"Marcela","family":"Castro1","sequence":"additional","affiliation":[{"name":"1. Divis\u00e3o de Pneumologia, Instituto do Cora\u00e7\u00e3o, Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8943-1947","authenticated-orcid":false,"given":"Jose","family":"Leonidas Alves-Jr1","sequence":"additional","affiliation":[{"name":"1. Divis\u00e3o de Pneumologia, Instituto do Cora\u00e7\u00e3o, Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2789-9143","authenticated-orcid":false,"given":"Rogerio","family":"Souza1","sequence":"additional","affiliation":[{"name":"1. Divis\u00e3o de Pneumologia, Instituto do Cora\u00e7\u00e3o, Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22288","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.            Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425-1436. https:\/\/doi.org\/10.1056\/NEJMra040291","DOI":"10.1056\/nejmra040291"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2.            Alves JL Jr, Gavilanes F, Jardim C, Fernandes CJCDS, Morinaga LTK, et al. Pulmonary arterial hypertension in the southern hemisphere: results from a registry of incident Brazilian cases. Chest. 2015;147(2):495-501. https:\/\/doi.org\/10.1378\/chest.14-1036","DOI":"10.1378\/chest.14-1036"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3.            Montani D, Savale L, Natali D, Ja\u00efs X, Herve P, Garcia G, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J. 2010;31(15):1898-1907. https:\/\/doi.org\/10.1093\/eurheartj\/ehq170","DOI":"10.1093\/eurheartj\/ehq170"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.            Langleben D, Orfanos SE, Giovinazzo M, Schlesinger RD, Hirsch AM, Blenkhorn F, et al. Acute vasodilator responsiveness and microvascular recruitment in idiopathic pulmonary arterial hypertension. Ann Intern Med. 2015;162(2):154-156. https:\/\/doi.org\/10.7326\/M14-1402","DOI":"10.7326\/m14-1402"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.            Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327(2):76-81. https:\/\/doi.org\/10.1056\/NEJM199207093270203","DOI":"10.1056\/nejm199207093270203"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6.            Sitbon O, Humbert M, Ja\u00efs X, Ioos V, Hamid AM, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111(23):3105-3111. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.104.488486","DOI":"10.1161\/circulationaha.104.488486"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7.            Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618-3731. https:\/\/doi.org\/10.1093\/eurheartj\/ehac237","DOI":"10.1093\/eurheartj\/ehad018"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.            Lau EM, Tamura Y, McGoon MD, Sitbon O. The 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: a practical chronicle of progress. Eur Respir J. 2015;46(4):879-882. https:\/\/doi.org\/10.1183\/13993003.01177-2015","DOI":"10.1183\/13993003.01177-2015"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9.            Alves JL Jr, Oleas FG, Souza R. Pulmonary Hypertension: Definition, Classification, and Diagnosis. Semin Respir Crit Care Med. 2017;38(5):561-570. https:\/\/doi.org\/10.1055\/s-0037-1606577","DOI":"10.1055\/s-0037-1606577"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10.          Costa EL, Jardim C, Bogossian HB, Amato MB, Carvalho CR, Souza R. Acute vasodilator test in pulmonary arterial hypertension: evaluation of two response criteria. Vascul Pharmacol. 2005;43(3):143-147. https:\/\/doi.org\/10.1016\/j.vph.2005.05.004","DOI":"10.1016\/j.vph.2005.05.004"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11.          Hoeper MM, Pittrow D, Opitz C, Gibbs JSR, Rosenkranz S, Gr\u00fcnig E, et al. Risk assessment in pulmonary arterial hypertension. Eur Respir J. 2018;51(3):1702606. https:\/\/doi.org\/10.1183\/13993003.02606-2017","DOI":"10.1183\/13993003.02606-2017"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12.          Hemnes AR, Zhao M, West J, Newman JH, Rich S, Archer SL, et al. Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2016;194(4):464-475. https:\/\/doi.org\/10.1164\/rccm.201508-1678OC","DOI":"10.1164\/rccm.201508-1678oc"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.          Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Gr\u00fcnig E, et al. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J. 2022;60(1):2102311. https:\/\/doi.org\/10.1183\/13993003.02311-2021","DOI":"10.1183\/13993003.02311-2021"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.          Hoeper MM, Kramer T, Pan Z, Eichstaedt CA, Spiesshoefer J, Benjamin N, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2):1700740. https:\/\/doi.org\/10.1183\/13993003.00740-2017","DOI":"10.1183\/13993003.00740-2017"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.          Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hyperten-sion. Eur Respir J. 2019;53(1):1801913. https:\/\/doi.org\/10.1183\/13993003.01913-2018","DOI":"10.1183\/13993003.01913-2018"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T16:47:28Z","timestamp":1678985248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jornaldepneumologia.com.br\/details\/3817\/en-US\/loss-of-response-to-calcium-channel-blockers-after-long-term-follow-up-treatment-in-patients-with-idiopathic-pulmonary-arterial-hypertension"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":15,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20220337","relation":{},"ISSN":["1806-3756"],"issn-type":[{"value":"1806-3756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]}}}